nach oben

Indian Journal of Otolaryngology and Head & Neck Surgery

Erschienen in:

05.01.2022 | Original Article

Eustachian Tube Functions in Concurrent Chemoradiotherapy for Head and Neck Cancer Patients

verfasst von: Akira Ohkoshi, Ryoukichi Ikeda, Jun Suzuki, Takaya Yamamoto, Ryo Ishii, Kenjiro Higashi, Shun Wakamori, Yuki Nakayama, Ayako Nakanome, Takenori Ogawa, Yukio Katori

Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery | Sonderheft 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Ototoxicity is a dose-limiting adverse event for concurrent chemoradiotherapy (CCRT) with high-dose cisplatin for locally advanced head and neck squamous cell carcinoma (HNSCC). Both irradiation to the Eustachian tube (ET) and weight loss are risk factors for patulous ET. The aim of this prospective, observational study was to elucidate the incidences of patulous ET conditions before and after CCRT in HNSCC patients by means of ET function tests. This prospective, observational study was conducted in 27 HNSCC patients who received CCRT with high-dose cisplatin, and ET function tests (sonotubometry and tubo-tympano-aerodynamic graphy) were performed before and 3 months after CCRT. Factors potentially affecting the incidence of patulous ET conditions after CCRT were evaluated. Of the 54 ears from 27 patients investigated, patulous ET conditions were observed in 12 ears (22.2%) from 9 patients (33.3%) before CCRT and 15 ears (27.8%) from 11 patients (40.7%) at 3 months after CCRT. Only patulous ET conditions before CCRT in each ear were significantly associated with patulous ET conditions after CCRT (p = 0.010). This is the first report to describe the incidences of patulous ET conditions before and after CCRT in HNSCC patients. HNSCC patients are potentially at higher risk of patulous ET.

Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21(1):92–98CrossRef

Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349(22):2091–2098CrossRef

Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH et al (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952CrossRef

Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19):1937–1944CrossRef

Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, version 3.2021. Available at:https://www.nccn.org/guidelines/category_1 Accessed March 1, 2021.

Ohkoshi A, Ishii R, Wakamori S, Nakayama Y, Yoshida T, Higashi K et al (2021) Serum selenium predicts achievement of full-dose cisplatin in concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a prospective, observational study. Oral Oncol 121:105475

Rybak LP, Mukherjea D, Jajoo S, Ramkumar V (2009) Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 219(3):177–186CrossRef

Hoek J, Bloemendal KM, van der Velden LA, van Diessen JN, van Werkhoven E, Klop WM et al (2016) Nephrotoxicity as a dose-limiting factor in a high-dose cisplatin-based chemoradiotherapy regimen for head and neck carcinomas. Cancers 8(2):21CrossRef

10.

Ishii R, Kato K, Ohkoshi A, Sato T, Hirano A, Ogawa T et al (2021) Simultaneous evaluation of symptoms, swallowing functions, and patient-reported swallowing difficulties and their correlations with ingestion status during definitive chemoradiotherapy for oropharyngeal and hypopharyngeal cancer. Support Care Cancer 29(2):955–964CrossRef

11.

Schmitt NC, Page BR (2018) Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients. Int J Audiol 57(sup4):S49-54CrossRef

12.

Pearson SE, Meyer AC, Adams GL, Ondrey FG (2006) Decreased hearing after combined modality therapy for head and neck cancer. Am J Otolaryngol 27(2):76–80CrossRef

13.

Theunissen EA, Bosma SC, Zuur CL, Spijker R, van der Baan S, Dreschler WA et al (2015) Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: a systematic review of the literature. Head Neck 37(2):281–292CrossRef

14.

Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC (2009) Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys 73(3):779–788CrossRef

15.

Bhandare N, Antonelli PJ, Morris CG, Malayapa RS, Mendenhall WM (2007) Ototoxicity after radiotherapy for head and neck tumors. Int J Radiat Oncol Biol Phys 67(2):469–479CrossRef

16.

Hsin CH, Tseng HC, Lin HP, Chen TH (2016) Post-irradiation otitis media, rhinosinusitis, and their interrelationship in nasopharyngeal carcinoma patients treated by IMRT. Eur Arch Otorhinolaryngol 273(2):471–474CrossRef

17.

Jain A, Banerjee PK, Manjunath D (2016) Effects of chemoradiation on hearing in patients with head and neck malignancies: experience at a tertiary referral care hospital. Indian J Otolaryngol Head Neck Surg 68(4):456–461CrossRef

18.

Malgonde MS, Nagpure PS, Kumar M (2015) Audiometric patterns in ototoxicity after radiotherapy and chemotherapy in patients of head and neck cancers. Indian J Palliat Care 21(2):164–167CrossRef

19.

Christensen JG, Wessel I, Gothelf AB, Homøe P (2018) Otitis media with effusion after radiotherapy of the head and neck: a systematic review. Acta Oncol 57(8):1011–1016CrossRef

20.

Ondrey FG, Greig JR, Herscher L (2000) Radiation dose to otologic structures during head and neck cancer radiation therapy. Laryngoscope 110(2 Pt 1):217–221CrossRef

21.

Takasaki K, Hirsch BE, Sando I (2000) Histopathologic study of the human eustachian tube and its surrounding structures following irradiation for carcinoma of the oropharynx. Arch Otolaryngol Head Neck Surg 126(4):543–546CrossRef

22.

Lambert EM, Gunn GB, Gidley PW (2016) Effects of radiation on the temporal bone in patients with head and neck cancer. Head Neck 38(9):1428–1435CrossRef

23.

Ikeda R, Kikuchi T, Oshima H, Kobayashi T (2020) Management of patulous eustachian tube. JMA J 3(2):101–108

24.

Luu K, Remillard A, Fandino M, Saxby A, Westerberg BD (2015) Treatment effectiveness for symptoms of patulous eustachian tube: a systematic review. Otol Neurotol 36(10):1593–1600CrossRef

25.

Hirai R, Oshima T (2020) Silicone plug insertion for treatment of refractory patulous eustachian tube after irradiation. Acta Oto-Laryngologica Case Reports 5(1):106–110CrossRef

26.

Kobayashi T, Morita M, Yoshioka S, Mizuta K, Ohta S, Kikuchi T et al (2018) Diagnostic criteria for patulous eustachian tube: a proposal by the japan otological society. Auris Nasus Larynx 45(1):1–5CrossRef

27.

Takata I, Ikeda R, Kawase T, Suzuki Y, Sato T, Katori Y et al (2017) Sonotubometric assessment for severity of patulous eustachian tube. Otol Neurotol 38(6):846–852CrossRef

28.

Ikeda R, Kawase T, Takata I, Suzuki Y, Sato T, Katori Y et al (2019) Width of patulous eustachian tube: comparison of assessment by sonotubometry and tubo-tympano-aerography. Otol Neurotol 40(4):e386–e392CrossRef

29.

Choi SW, Kim J, Lee HM, Oh SJ, Lee IW, Goh EK et al (2018) Prevalence and incidence of clinically significant patulous Eustachian tube: a population-based study using the Korean National Health Insurance Claims Database. Am J Otolaryngol 39(5):603–608CrossRef

30.

van Bokhorst-de van der Schueren MA, van Leeuwen PA, Sauerwein HP, Kuik DJ, Snow GB, Quak JJ (1997) Assessment of malnutrition parameters in head and neck cancer and their relation to postoperative complications. Head Neck 19(5):419–425

31.

De Sanctis V, Bossi P, Sanguineti G, Trippa F, Ferrari D, Bacigalupo A et al (2016) Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements. Crit Rev Oncol Hematol 100:147–166CrossRef

32.

Ohkoshi A, Kato K, Ogawa T, Nakanome A, Ishii R, Katori Y (2020) Improvement of a delayed swallowing reflex following treatment for advanced head and neck cancer. Cancers Head Neck 5:8CrossRef

33.

Kawamura Y, Ikeda R, Kikuchi T, Miyazaki H, Kawase T, Katori Y et al (2019) The characteristic of patulous eustachian tube patients diagnosed by the JOS diagnostic criteria. PLoS One 14(12):e0226908

Titel: Eustachian Tube Functions in Concurrent Chemoradiotherapy for Head and Neck Cancer Patients
verfasst von: Akira Ohkoshi
Ryoukichi Ikeda
Jun Suzuki
Takaya Yamamoto
Ryo Ishii
Kenjiro Higashi
Shun Wakamori
Yuki Nakayama
Ayako Nakanome
Takenori Ogawa
Yukio Katori
Publikationsdatum: 05.01.2022
Verlag: Springer India
Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery / Ausgabe Sonderheft 3/2022
Print ISSN: 2231-3796
Elektronische ISSN: 0973-7707
DOI: https://doi.org/10.1007/s12070-021-03058-x

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Eustachian Tube Functions in Concurrent Chemoradiotherapy for Head and Neck Cancer Patients

Abstract

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 3/2022

Will Vestibular Migraine Pathology Lead to Ischemic Changes in Brain Tissue in Later Age?

Warthin like Variant of Papillary Carcinoma Thyroid with BRAF Mutation

Outcome of Universal Neonatal Hearing Screening Programme at a Tertiary Care Centre: A Prospective Study

Compare the Efficacy of Open Reduction and Internal Fixation of Mandibular Fractures With and Without Use of Intra-Operative Inter-Maxillary Fixation

Allergic Fungal Otomastoiditis: A Case Report and Review of Literature

Bilateral Puffy Orbits in a toddler: Therapeutic Challenges

Neu im Fachgebiet HNO

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Update HNO